The deal seeks to strengthen the drugmaker’s portfolio of respiratory vaccines and help it move on from pipeline setbacks.

A soon-to-be-released documentary film aims to change the conversation around hemophilia, a condition in which many female ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

Sanofi and Kling Bio have entered into a partnership aimed at accelerating the discovery of neutralising antibodies. The ...

The deal complements an existing partnership with Novavax that encompasses R&D of combination vaccines for Covid-19 and flu.

According to the terms of the agreement, Sanofi will acquire London-based Vicebio’s entire share capital for an upfront ...

Sanofi is buying Vicebio, a biotech, that is developing vaccines for two viruses using the molecular clamp technology ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

Vicebio, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, has ...

Sanofi agreed to buy UK vaccine developer Vicebio Ltd. for as much as $1.6 billion, as it seeks to expand in respiratory ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...